Your session is about to expire
← Back to Search
Brentuximab + Lenalidomide for T-Cell Lymphoma
Study Summary
This trial is studying brentuximab vedotin and lenalidomide to see how well they work in treating patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had cancer before, but it was either early stage, treated over 2 years ago, or under surveillance without treatment.I do not have any current infections or recent major infections that required IV antibiotics or hospitalization.I have a significant history of liver problems, including hepatitis, alcohol abuse, or cirrhosis.I can understand and willingly sign a consent form.I have a type of skin lymphoma that is not mycosis fungoides.I have severe nerve damage in my hands or feet.I have active hepatitis B or C, or need to take precautions due to hepatitis B.My skin lymphoma has returned or didn't respond after initial treatments.I am currently on medication to suppress my immune system.My liver enzymes are within acceptable limits for someone with lymphoma affecting the liver.I've been cancer-free for 5 years, except for minor skin cancers or early-stage prostate cancer.My skin lymphoma has returned or didn't respond to treatment after 2 skin treatments or 1 body-wide treatment.I don't have any health issues that could affect my safety or interfere with the study medication.My condition worsened within 30 days after my last brentuximab vedotin treatment.I have been treated with lenalidomide before.My skin lymphoma has changed into a more aggressive form.I have T cell lymphoma, received chemotherapy, and my disease can be measured by scans.My cancer was tested for CD30, but it doesn't need to be positive.I am following strict birth control and pregnancy testing as required.I haven't had any live-virus vaccines in the last 28 days and don't need any during the study.My lymphoma has not spread to my brain or spinal cord.I have not had major surgery in the last 6 weeks.I have never had progressive multifocal leukoencephalopathy.I have never had an allogeneic stem cell transplant.I have issues that prevent me from properly swallowing pills or absorbing medication.My T cell lymphoma came back after a stem cell transplant.I have taken brentuximab vedotin but did not worsen during or right after treatment, and it's been 3 months since my last dose.I stopped all cancer treatments at least 1 week ago, or longer if needed, but may still be on low-dose steroids.My heart condition limits my physical activity.I am able to care for myself and perform daily activities.I may have taken steroids for my condition up to a day before joining the study.
- Group 1: Treatment (brentuximab vedotin, lenalidomide)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For which diseases is Lenalidomide typically prescribed?
"Through Lenalidomide, patients diagnosed with chronic lymphocytic leukemia or Hodgkin disease can receive proper treatment after having gone through two prior courses of chemotherapy."
Are there any previous experiments involving Lenalidomide that the medical community can refer to?
"Currently, 325 studies based on lenalidomide are being conducted. Of these, 61 have entered the third phase of clinical trials. Though Chicago is a major hub for Lenalidomide research, there are 14,926 locales where related examinations are taking place."
Has the FDA sanctioned Lenalidomide for therapeutic use?
"Lenalidomide attained a score of 2 since the medication has not been verified to be effective yet, but there is previous data affirming its safety."
Does this scientific experiment offer any opportunity for enrollment?
"Unfortunately, this trial is no longer in the recruitment phase. It was initially posted on March 16th 2018 and last edited November 1st 2022. If you are still seeking a medical study to join, there are 2662 studies actively recruiting patients with granulomatous slack skin and 325 trials for Lenalidomide that have open slots for enrolment."
What is the target enrollment for this research endeavor?
"This research study is no longer recruiting participants, as the trial was last updated on November 1st 2022. Fortunately, there are 2,662 studies actively seeking patients with granulomatous slack skin and 325 trials for Lenalidomide still open to enrolment."
Share this study with friends
Copy Link
Messenger